Gilead Sciences, Inc. : Gilead Announces Phase 2 Results for Sofosbuvir-Based ... 4-traders (press release) In a second study conducted among post-transplant HCV patients (Study 0126), patients with established recurrent HCV infection following liver transplantation received 24 weeks of sofosbuvir/RBV therapy. Seventy-seven percent (n=27/35) of patients in ... |
